


1. (Currently Amended) A compound of formula (I)



or a pharmaceutically acceptable salt or prodrug thereof, wherein

--- is absent or is a single bond;

X₁ is selected from the group consisting of N and CR₁;

X₂ is selected from the group consisting of N and CR₂NR₂;

X₃ is selected from the group consisting of N, NR₃, and CR₃;

X₄ is a bond; or selected from the group consisting of N and CR₄;


X₅ is selected from the group consisting of N and C;

provided that at least one of X₁, X₂, X₃, and X₄ is N;

Z₁ is selected from the group consisting of O, NH, and S;

Z₂ is a bond or selected from the group consisting of NH and O;

L is selected from the group consisting of alkenylene, alkylene, alkynylene,

cycloalkylene, , -(CH₂)_mO(CH₂)_n-, and N(R_Y), wherein the left end of -(CH₂)_mO(CH₂)_n- is attached to Z₂ and the right end is attached to R₉;

m and n are each independently 0-6;

R_Y is selected from the group consisting of hydrogen and alkyl;

R₁, R₃, R₅, R₆, and R₇ are each independently selected from the group consisting of hydrogen, alkenyl, alkoxy, ~~alkoxyalkoxy~~, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylthio, ~~alkynyl~~, carboxy, carboxyalkyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylalkyl, ~~formyl~~, ~~formylalkyl~~, haloalkoxy, haloalkyl, haloalkylthio, halogen, hydroxy, hydroxyalkyl, mercapto, mercaptoalkyl, ~~nitro~~, (CF₃)₂(HC)C-, ~~NR_AS(O)₂R_B~~, -S(O)₂OR_A, -S(O)₂R_B, -NZ_AZ_B, (NZ_AZ_B)alkyl, (NZ_AZ_B)carbonyl, (NZ_AZ_B)carbonylalkyl and (NZ_AZ_B)sulfonyl, wherein Z_A and Z_B are each independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, formyl, aryl, and arylalkyl;

~~R₂ and R₄ are each~~ independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylthio, ~~alkynyl~~, carboxy, carboxyalkyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylalkyl, ~~formyl~~, ~~formylalkyl~~, haloalkoxy, haloalkyl, haloalkylthio, halogen, hydroxy,

hydroxyalkyl, mercapto, ~~mercaptoalkyl~~, nitro, $(\text{CF}_3)_2(\text{HO})\text{C}-$, $-\text{NR}_\text{A}\text{S}(\text{O})_2\text{R}_\text{B}$, $-\text{S}(\text{O})_2\text{OR}_\text{A}$, $-\text{S}(\text{O})_2\text{R}_\text{B}$, $-\text{NZ}_\text{A}\text{Z}_\text{B}$, $(\text{NZ}_\text{A}\text{Z}_\text{B})\text{alkyl}$, $(\text{NZ}_\text{A}\text{Z}_\text{B})\text{alkylcarbonyl}$, $(\text{NZ}_\text{A}\text{Z}_\text{B})\text{carbonyl}$, $(\text{NZ}_\text{A}\text{Z}_\text{B})\text{carbonylalkyl}$, and $(\text{NZ}_\text{A}\text{Z}_\text{B})\text{sulfonyl}$, $(\text{NZ}_\text{A}\text{Z}_\text{B})\text{C}(=\text{NH})$, $(\text{NZ}_\text{A}\text{Z}_\text{B})\text{C}(=\text{NCN})\text{NH}$, and $(\text{NZ}_\text{A}\text{Z}_\text{B})\text{C}(=\text{NH})\text{NH}$;

R_A is selected from the group consisting of hydrogen and alkyl;

R_B is selected from the group consisting of alkyl, aryl, and arylalkyl;

$\text{R}_{8\text{a}}$ is selected from the group consisting of hydrogen and alkyl;

$\text{R}_{8\text{b}}$ is absent when X_5 is N or $\text{R}_{8\text{b}}$ is selected from the group consisting of hydrogen, alkoxy, alkoxyalkyl, alkyl, alkylcarbonyloxy, alkylsulfonyloxy, halogen, and hydroxy when X_5 is C; and

R_9 is selected from the group consisting of hydrogen, aryl, cycloalkyl, and heterocycle.

2-76. (Cancelled)

77. (Currently Amended) The compound according to claim 1 wherein

~~---~~ is absent;

~~X_1 is CR_1 ;~~

X_2 is N;

~~X_3 is NR_3 ; and~~

~~X_4 is a bond.~~

~~$\text{R}_{8\text{b}}$ is absent;~~

L is alkylene; and

R_9 is aryl.

78. (Cancelled)

79. (Currently Amended) The compound according to claim 77 wherein

X_5 is N;

R_1 , R_5 , R_6 and R_7 are each hydrogen; and

~~$\text{R}_{8\text{b}}$ is absent;~~

Z_1 is O;

Z_2 is NH;

L is alkylene;

R_9 is aryl wherein said aryl is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and $-\text{NZ}_\text{C}\text{Z}_\text{D}$; and

Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl.

80. (Original) The compound according to claim 79 selected from the group consisting of

N-(3,4-dichlorobenzyl)-N'-1H-indazol-4-ylurea;

N-1H-indazol-4-yl-N'-[4-(1-piperidinyl)benzyl]urea;
 N-[3-fluoro-4-(1-piperidinyl)benzyl]-N'-1H-indazol-4-ylurea;
 N-1H-indazol-4-yl-N'-[4-(1-pyrrolidinyl)benzyl]urea;
 N-[3-fluoro-4-(1-pyrrolidinyl)benzyl]-N'-1H-indazol-4-ylurea;
 N-[4-(1-azepanyl)benzyl]-N'-1H-indazol-4-ylurea;
 N-[4-(1-azepanyl)-3-fluorobenzyl]-N'-1H-indazol-4-ylurea;
 N-(1-methyl-1H-indazol-4-yl)-N'-[4-(1-piperidinyl)benzyl]urea;
 N-[3-fluoro-4-(1-piperidinyl)benzyl]-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-(1-methyl-1H-indazol-4-yl)-N'-[4-(1-pyrrolidinyl)benzyl]urea;
 N-[3-fluoro-4-(1-pyrrolidinyl)benzyl]-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-[4-(1-azepanyl)benzyl]-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-[4-(1-azepanyl)-3-fluorobenzyl]-N'-(1-methyl-1H-indazol-4-yl)urea;
 methyl 4-({[(1-naphthylmethyl)amino]carbonyl}amino)-1H-indazole-1-carboxylate;
 methyl 4-({[(1,1'-biphenyl-3-ylmethyl)amino]carbonyl}amino)-1H-indazole-1-carboxylate;
 methyl 4-({[(2-chlorobenzyl)amino]carbonyl}amino)-1H-indazole-1-carboxylate;
 methyl 4-({[2-fluoro-5-(trifluoromethyl)benzyl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;
 N-(1,1'-biphenyl-3-ylmethyl)-N'-1H-indazol-4-ylurea;
 N-(2-chlorobenzyl)-N'-1H-indazol-4-ylurea;
 N-[2-fluoro-5-(trifluoromethyl)benzyl]-N'-1H-indazol-4-ylurea;
 N-[2-(2,4-dimethylphenyl)ethyl]-N'-1H-indazol-4-ylurea;
 N-[2-(3,4-dichlorophenyl)ethyl]-N'-1H-indazol-4-ylurea;
 N-1H-indazol-4-yl-N'-[2-(4-methylphenyl)ethyl]urea;
 N-[4-azepan-1-yl-3-(trifluoromethyl)benzyl]-N'-1H-indazol-4-ylurea;
 N-[4-azepan-1-yl-2-(trifluoromethyl)benzyl]-N'-1H-indazol-4-ylurea;
 N-[4-(2-azabicyclo[2.2.1]hept-2-yl)-2-(trifluoromethyl)benzyl]-N'-1H-indazol-4-ylurea;
 N-[4-(8-azabicyclo[3.2.1]oct-8-yl)-2-(trifluoromethyl)benzyl]-N'-1H-indazol-4-ylurea;
 N-[4-(8-azabicyclo[3.2.1]oct-8-yl)-3-fluorobenzyl]-N'-1H-indazol-4-ylurea;
 N-(3-chloro-4-azepan-1-ylbenzyl)-N'-1H-indazol-4-ylurea;
 N-[(1S)-1-(4-bromophenyl)ethyl]-N'-1H-indazol-4-ylurea;
 N-(3-bromo-4-fluorobenzyl)-N'-1H-indazol-4-ylurea;
 N-(2,4-dimethylbenzyl)-N'-1H-indazol-4-ylurea;
 N-(4-chlorobenzyl)-N'-1H-indazol-4-ylurea;
 N-[3-fluoro-4-(trifluoromethyl)benzyl]-N'-1H-indazol-4-ylurea;
 N-1H-indazol-4-yl-N'-(4-methylbenzyl)urea;
 N-1H-indazol-4-yl-N'-[3-(trifluoromethoxy)benzyl]urea;
 N-(3-chloro-4-fluorobenzyl)-N'-1H-indazol-4-ylurea;
 N-(3,4-dimethylbenzyl)-N'-1H-indazol-4-ylurea;
 N-[3-fluoro-5-(trifluoromethyl)benzyl]-N'-1H-indazol-4-ylurea;
 N-(2-chloro-4-azepan-1-ylbenzyl)-N'-1H-indazol-4-ylurea;
 N-(2,3-dichlorobenzyl)-N'-1H-indazol-4-ylurea;
 N-1H-indazol-4-yl-N'-{4-[(trifluoromethyl)thio]benzyl}urea;

- N-1H-indazol-4-yl-N'-[3-(trifluoromethyl)benzyl]urea;
 N-(3,5-difluoro-4-azepan-1-ylbenzyl)-N'-1H-indazol-4-ylurea;
 N-[4-(8-azabicyclo[3.2.1]oct-8-yl)-3,5-difluorobenzyl]-N'-1H-indazol-4-ylurea;
 N-(4-chlorobenzyl)-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-[4-(8-azabicyclo[3.2.1]oct-8-yl)-2-chlorobenzyl]-N'-1H-indazol-4-ylurea;
 methyl 4-[(4-(8-azabicyclo[3.2.1]oct-8-yl)-3-(trifluoromethyl)benzyl)amino]carbonylamino]-1H-indazole-1-carboxylate;
 N-[4-(8-azabicyclo[3.2.1]oct-8-yl)-3-chlorobenzyl]-N'-1H-indazol-4-ylurea;
 N-[4-(8-azabicyclo[3.2.1]oct-8-yl)benzyl]-N'-1H-indazol-4-ylurea;
 N-(4-tert-butylbenzyl)-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-[3-fluoro-4-(trifluoromethyl)benzyl]-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-[4-chloro-3-(trifluoromethyl)benzyl]-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-(3,4-dichlorobenzyl)-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-(2,4-dichlorobenzyl)-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-(4-ethylbenzyl)-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-(2-chlorobenzyl)-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-(4-fluorobenzyl)-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-(2-fluorobenzyl)-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-[1-(4-bromophenyl)ethyl]-N'-(1-methyl-1H-indazol-4-yl)urea; and
 N-(1-methyl-1H-indazol-4-yl)-N'-{4-[(trifluoromethyl)thio]benzyl}urea.
81. (Currently Amended) The compound according to claim 77 wherein
 R_{8a} , R_1 , R_5 , R_6 and R_7 are each hydrogen;
 R_{8b} is absent;
 X_5 is N;
 Z_1 is O;
 Z_2 is NH;
 L is alkylene wherein the alkylene is $-CH_2-$;
 R_9 is aryl wherein said aryl is phenyl substituted with 2 substituents independently
 selected from the group consisting of (8-azabicyclo[3.2.1]oct-8-yl), trifluoromethyl, and -
 Cl;
 and
 R_3 is selected from the group consisting of hydrogen and alkoxycarbonyl.
82. (Currently Amended) The compound according to claim 77 wherein
 R_{8a} , R_1 , R_5 , R_6 and R_7 are each hydrogen;
 R_{8b} is absent;
 X_5 is N;
 Z_1 is O;
 Z_2 is NH;
 L is alkylene wherein the alkylene is $-CH_2-$;
 R_9 is aryl wherein said aryl is 4-(8-azabicyclo[3.2.1]oct-8-yl)-3-(trifluoromethyl)phenyl; and
 R_3 is selected from the group consisting of hydrogen and alkoxycarbonyl.
83. (Currently Amended) The compound according to claim 77 wherein

R_{8a} , R_1 , R_5 , R_6 and R_7 are each hydrogen;

R_{8b} is absent;

X_5 is N;

Z_1 is O;

Z_2 is NH;

L is alkylene wherein the alkylene is $-CH_2-$;

R_9 is aryl wherein said aryl is 2-chloro-4-(8-azabicyclo[3.2.1]oct-8-yl)phenyl; and

R_3 is selected from the group consisting of hydrogen and alkoxycarbonyl.

84. (Original) The compound according to claim 81 selected from the group consisting of

N-[4-(8-azabicyclo[3.2.1]oct-8-yl)-2-chlorobenzyl]-N'-1H-indazol-4-ylurea; and

N-[4-(8-azabicyclo[3.2.1]oct-8-yl)-3-(trifluoromethyl)benzyl]-N'-1H-indazol-4-ylurea.

85. (Currently Amended) The compound according to claim 77 wherein

X_5 is N;

R_1 , R_6 and R_7 are each hydrogen;

R_5 is alkyl; and

R_{8b} is absent;

Z_1 is O;

Z_2 is NH;

L is alkylene;

R_9 is aryl wherein said aryl is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and $-NZ_CZ_D$; and

Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl.

86. (Original) The compound according to claim 85 selected from the group consisting of

N-(4-tert-butylbenzyl)-N'-(7-methyl-1H-indazol-4-yl)urea;

N-(7-methyl-1H-indazol-4-yl)-N'-[4-(trifluoromethyl)benzyl]urea; and

N-(7-methyl-1H-indazol-4-yl)-N'-{4-[(trifluoromethyl)thio]benzyl}urea.

87. (Currently Amended) The compound according to claim 77 wherein

X_5 is N;

R_1 , R_5 , R_6 and R_7 are each hydrogen;

R_3 is alkyl;

R_{8b} is absent;

Z_1 is O;

Z_2 is NH;

L is alkylene; and

R_9 is aryl wherein said aryl is selected from the group consisting of naphthyl and phenyl.

88. (Original) The compound according to claim 87 selected from the group consisting of

N-1H-indazol-4-yl-N'-(1-naphthylmethyl)urea; and
N-1H-indazol-4-yl-N'-(3-phenylpropyl)urea.

89. (Currently Amended) The compound according to claim 77 wherein

X_5 is N;

R_1 , R_5 , R_6 and R_7 are each hydrogen; and

R_{8b} is absent;

Z_1 is O;

Z_2 is NH;

L is alkylene; and

R_9 is heterocycle wherein said heterocycle is pyridinyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6,-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D.

90. (Original) The compound according to claim 89 that is N-1H-indazol-4-yl-N'-{[6-(trifluoromethyl)-3-pyridinyl]methyl}urea.

91. (Currently Amended) The compound according to claim 77 wherein


X_5 is N;

R_{8b} is absent;

Z_1 is O;

Z_2 is NH;

L is



R_9 is heterocycle.

92. (Currently Amended) The compound according to claim 77 wherein

X_5 is N;


R_1 , R_5 , R_6 and R_7 are each hydrogen;

R_{8b} is absent;

Z_1 is O;

Z_2 is NH;

L is



R_9 is heterocycle wherein said heterocycle is pyridinyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZCZD; and

ZC and ZD are independently selected from the group consisting of hydrogen and alkyl.

93. (Currently Amended) AThe compound according to claim 92 that is N-(1-methyl-1H-indazol-4-yl)-4-[4-(trifluoromethyl)-2-pyridinyl]-1-piperazinecarboxamide.

94. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof.

95. (Currently Amended) A method of treating a disorder wherein the disorder is ameliorated by inhibiting vanilloid receptor subtype 1 (VR1) receptor, and wherein the disorder is selected from the group comprising pain, bladder overactivity, urinary incontinence and inflammatory thermal hyperalgesia in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof.

96. (Currently Amended) A method of treating bladder overactivity in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof.

97. (Currently Amended) A method of treating urinary incontinence in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof.

98. (New) A method of treating pain in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof.

99. (New) A method of treating inflammatory thermal hyperalgesia in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof.